Advertisement

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement

Jun

01

Today In Oncology

PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer

Adjuvant Selpercatinib Improves Event-Free Survival in RET-Positive Early-Stage NSCLC

Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases

Many Patients With Limited Sentinel Node–Positive Breast Cancer Can Safely Avoid Axillary Dissection, Study Shows

Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC

Advertisement

© 2026 HSP News Service, L.L.C.